Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Cholera - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Cholera - Pipeline Review, H1 2015', provides an overview of the Cholera's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Cholera, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cholera and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Cholera - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Cholera and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Cholera products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Cholera pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cholera - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cholera pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Cholera Overview 6 Therapeutics Development 7 Pipeline Products for Cholera - Overview 7 Pipeline Products for Cholera - Comparative Analysis 8 Cholera - Therapeutics under Development by Companies 9 Cholera - Therapeutics under Investigation by Universities/Institutes 10 Cholera - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Cholera - Products under Development by Companies 14 Cholera - Products under Investigation by Universities/Institutes 15 Cholera - Companies Involved in Therapeutics Development 16 Beijing Minhai Biotechnology Co., Ltd 16 Napo Pharmaceuticals, Inc. 17 PaxVax 18 Cholera - Therapeutics Assessment 19 Assessment by Monotherapy Products 19 Assessment by Target 20 Assessment by Mechanism of Action 21 Assessment by Route of Administration 22 Assessment by Molecule Type 23 Drug Profiles 25 AKT-10082 - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 cholera (trivalent) vaccine - Drug Profile 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 crofelemer DR - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 PXVX-0200 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Cholera - Recent Pipeline Updates 31 Cholera - Dormant Projects 35 Cholera - Discontinued Products 36 Cholera - Product Development Milestones 37 Featured News & Press Releases 37 Dec 08, 2014: PaxVax Announces Primary Endpoints Met in Phase 3 Cholera Vaccine Trial 37 Sep 30, 2014: Specialty Vaccine Company PaxVax to Present at 13th Annual BIO Investor Forum 37 Jul 01, 2014: Specialty Vaccine Company PaxVax Announces Positive Efficacy Results for Phase 3 Cholera Challenge Study 38 May 27, 2014: Specialty Vaccine Company PaxVax to Present at the Jefferies 2014 Global Healthcare Conference 39 Jan 09, 2014: PaxVax Announces Positive Interim Results for Phase 3 Cholera Challenge Study; Clinical Trial Program to Proceed as Planned 39 Sep 06, 2013: PaxVax Initiates Phase 3 Clinical Trial Challenge Studies for Single-Dose Oral Cholera Vaccine 41 Nov 14, 2012: PaxVax Presents Phase I Clinical Trial Results Of Single-dose Cholera Vaccine At 2012 ASTMH Annual Meeting 42 Mar 19, 2012: FDA Accepts PaxVax's IND For Single-Dose Oral Cholera Vaccine 42 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 45
List of Tables Number of Products under Development for Cholera, H1 2015 7 Number of Products under Development for Cholera - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Late Stage Development, H1 2015 11 Comparative Analysis by Clinical Stage Development, H1 2015 12 Comparative Analysis by Early Stage Development, H1 2015 13 Products under Development by Companies, H1 2015 14 Products under Investigation by Universities/Institutes, H1 2015 15 Cholera - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015 16 Cholera - Pipeline by Napo Pharmaceuticals, Inc., H1 2015 17 Cholera - Pipeline by PaxVax, H1 2015 18 Assessment by Monotherapy Products, H1 2015 19 Number of Products by Stage and Target, H1 2015 20 Number of Products by Stage and Mechanism of Action, H1 2015 21 Number of Products by Stage and Route of Administration, H1 2015 22 Number of Products by Stage and Molecule Type, H1 2015 24 Cholera Therapeutics - Recent Pipeline Updates, H1 2015 31 Cholera - Dormant Projects, H1 2015 35 Cholera - Discontinued Products, H1 2015 36
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
